(87 days)
Not Found
No
The device description and performance studies focus on a physical orthotic device and its clinical efficacy, with no mention of AI or ML technologies.
Yes
The device is indicated for use in patients with primary snoring or snoring and mild OSA, and to prevent symptoms of nocturnal parafunctional jaw activity, all of which are conditions that impact health and well-being. The performance studies also show its efficacy in reducing RDI in patients with OSA.
No
Explanation: The device is described as an "anti-snoring device" and a "mandibular advancement and tongue positioning orthotic" indicated for treating snoring and mild OSA. Its function is to increase pharyngeal air space and prevent symptoms of nocturnal parafunctional jaw activity, which are therapeutic actions, not diagnostic ones.
No
The device description clearly outlines physical components: a mandibular occlusal bite plate, an adjustable external maxillary lip shield, and a wide occlusal surface. This indicates a hardware-based medical device, not a software-only one.
No, this device is not an IVD (In Vitro Diagnostic).
Here's why:
- IVD Definition: In Vitro Diagnostic devices are used to examine specimens taken from the human body (like blood, urine, tissue) to provide information for diagnosis, monitoring, or screening.
- Snore-Aid®plus Function: The Snore-Aid®plus is a physical device that is placed in the mouth to mechanically adjust the jaw and tongue position. It does not analyze any biological samples.
- Intended Use: The intended use is to treat snoring and mild OSA by physically altering the airway space and preventing nocturnal parafunctional jaw activity. This is a therapeutic intervention, not a diagnostic test.
The information provided clearly describes a physical medical device used for treatment, not a device used for in vitro diagnostic testing.
N/A
Intended Use / Indications for Use
Snore-Aid®plus is a perscribed anti-snoring device.
Snore-Aid®plus is indicated for use in patients with primary snoring A. or snoring and mild OSA (obstructive sleep apnea) where mandibular advancement and elevation of the tongue can increase a patient' s pharyngeal air space.
Snore-Aid®ø/us is indicated to prevent symptoms of nocturnal B. parafunctional jaw activity in patients undergoing treatment for snoring and OSA by mandibular advancement and tongue positioning.
Product codes
LRK
Device Description
Snore-Aid@plus is a single plate mandibular advancement and tongue positioning orthotic consisting of: (1) a flat mandibular occlusal bite plate, (2) an adjustable external maxillary lip shield, and (3) a wide occlusal surface. The occlusal bite plate provides dental stability, protects the TMJ from occlusal loading and prevents muscle soreness due It also actively elevates and positions the tongue anteriorly to bruxism. and dorsally against the palate, thereby increasing the patency of the airway.
Mentions image processing
Not Found
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Not Found
Anatomical Site
pharyngeal air space, TMJ, jaw
Indicated Patient Age Range
Not Found
Intended User / Care Setting
healthcare professional
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Not Found
Summary of Performance Studies (study type, sample size, AUC, MRMC, standalone performance, key results)
Clinical testing of the Snore-Aid@plus (MAPTO) appliance was done on 25 subjects who were diagnosed with snoring and mild to severe OSA. Twelve channel polysomnography was used to test subjects during full night sleep studies which were done pretreatment and repeated 4 weeks post-treatment. Treatment success was defined as a 50% reduction in RDI and a post-treatment RDI≤ 10. In 18 of 18 patients who had an initial RDI ≤30 there was treatment success. In 7 individuals who had severe apnea (RDI > 30) all achieved a reduction in RDI which was below of the pretreatment index, but only one achieved a RDI≤10. In none of the subjects was there any indication of TMJ pain or muscle sorness. None of the subjects reported bite changes upon awakening from sleep. Two patients reported nocturnal bruxism which caused temporary soreness of incisor teeth.
Key Metrics (Sensitivity, Specificity, PPV, NPV, etc.)
RDI (Respiratory Disturbance Index), 50% reduction in RDI, post-treatment RDI ≤ 10
Predicate Device(s)
Reference Device(s)
Not Found
Predetermined Change Control Plan (PCCP) - All Relevant Information
Not Found
§ 872.5570 Intraoral devices for snoring and intraoral devices for snoring and obstructive sleep apnea.
(a)
Identification. Intraoral devices for snoring and intraoral devices for snoring and obstructive sleep apnea are devices that are worn during sleep to reduce the incidence of snoring and to treat obstructive sleep apnea. The devices are designed to increase the patency of the airway and to decrease air turbulence and airway obstruction. The classification includes palatal lifting devices, tongue retaining devices, and mandibular repositioning devices.(b)
Classification. Class II (special controls). The special control for these devices is the FDA guidance document entitled “Class II Special Controls Guidance Document: Intraoral Devices for Snoring and/or Obstructive Sleep Apnea; Guidance for Industry and FDA.”
0
JUL 22 1999
Concept, Development & Production of Specialized Dental Technology K99 1449
510(k) Summary
April 21,1999
William A. Belfer, D.M.D., M.Sc.D. c/o Dental Imagineers & Associates 804 West Park Avenue Ocean, New Jersey 07712
(732) 493-4747 phone: fax: (732) 493-4742
Snore-Aid@plus Device/Trade name: Mandibular Advancement and Tongue Positioning Descriptive name: Orthotic (MATPO) Anti-Snoring Device Common name: Device, Anti-Snoring Classification name:
Substantial Equivalence Device: The Snore-Aid®plus is substantially equivalent to the Snore Free® K955336 (also known as the Rest Assured® appliance) and the Snore Guard® K882303 appliances.
Description of Device:
Snore-Aid@plus is a single plate mandibular advancement and tongue positioning orthotic consisting of: (1) a flat mandibular occlusal bite
1
plate, (2) an adjustable external maxillary lip shield, and (3) a wide occlusal surface. The occlusal bite plate provides dental stability, protects the TMJ from occlusal loading and prevents muscle soreness due It also actively elevates and positions the tongue anteriorly to bruxism. and dorsally against the palate, thereby increasing the patency of the airway.
The Snore Free® and Snore Guard® utilize a single unit maxillary plate and a mandibular guide plane to advance the lower jaw. The Snore-Aid®plus utilizes the mandibular occlusal bite plate to hold the lower jaw forward and buttresses against the maxillary lip via the use of a maxillary external lip shield.
The external lip shield is adjustable horizontally upon an anterior extension of the occlusal bite plate which extends between the lips.
Intended Use:
Snore-Aid®plus is a perscribed anti-snoring device.
Snore-Aid®plus is indicated for use in patients with primary snoring A. or snoring and mild OSA (obstructive sleep apnea) where mandibular advancement and elevation of the tongue can increase a patient' s pharyngeal air space.
Snore-Aid®ø/us is indicated to prevent symptoms of nocturnal B. parafunctional jaw activity in patients undergoing treatment for snoring and OSA by mandibular advancement and tongue positioning.
Characteristics: Technological -
The Snore-Aid®plus, Snore Free®, and Snore Guard® appliances are similar in that they all are individually customized and they all advance the lower jaw and increase airway space. The predicate devices have no means of actively elevating the tongue. However, Snore-Aid®plus elevates the tongue against the palate even if the mandible is not fully advanced, and thereby efficacy is enhanced.
Snore-Aid@plus and Snore Free® have full occlusal coverage to prevent occlusal bite changes. Moreover, the occlusal bite plate of Snore-Aid®plus can be equilibrated as a splint to influence occlusal function
2
and protect against parafunctional habits. SnoreGuard® has only partial occlusal coverage.
In the Snore Free® and Snore Guard® devices the maxillary plate and the mandibular guide plate provide the advancement function, but there is no protective mechanism for the TMJ. Snore-Aid®plus uses an external lip shield in lieu of the maxillary plate of the SnoreFree® and SnoreGuard®. It permits the mandible freedom of vertical and lateral motion. Furthermore, it allows the device to be adjustabled to fit different jaw sizes and it is a convenient means of titrating the mandibular advancement. SnoreFree® and SnoreGuard® require remolding in order to adjust the mandibular advancement and there is little if any freedom of lateral jaw motion.
Clinical Data:
Clinical testing of the Snore-Aid@plus (MAPTO) appliance was done on 25 subjects who were diagnosed with snoring and mild to severe OSA. Twelve channel polysomnography was used to test subjects during full night sleep studies which were done pretreatment and repeated 4 weeks post-treatment. Treatment success was defined as a 50% reduction in RDI and a post-treatment RDI≤ 10. In 18 of 18 patients who had an initial RDI ≤30 there was treatment success. In 7 individuals who had severe apnea (RDI > 30) all achieved a reduction in RDI which was below of the pretreatment index, but only one achieved a RDI≤10. In none of the subjects was there any indication of TMJ pain or muscle sorness. None of the subjects reported bite changes upon awakening from sleep. Two patients reported nocturnal bruxism which caused temporary soreness of incisor teeth.
Conclusion:
Snore-Aid@plus is appropriate for its intended use.
3
Image /page/3/Picture/1 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo is a circular seal with the words "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" around the perimeter. Inside the circle is an abstract image of a stylized caduceus, a symbol often associated with medicine and healthcare.
Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850
Jul 2 2 1999
William A. Belfer, D.M.D., M.Sc.D. Chief Executive Officer Dental Imagineers & Associates 804 West Park Avenue Ocean, New Jersey 07712
Re : K991449 Snore-Aid® plus Trade Name: Requlatory Class: Unclassified LRK Product Code: Dated: April 21, 1999 Received: April 26,1999
Dear Dr. Belfer:
We have reviewed your Section 510(k) notification of intent to market the device referenced above and we have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act). You may, therefore, market the device, subject to the general controls provisions The general controls provisions of the Act of the Act. include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.
If your device is classified (see above) into either class II (Special Controls) or class III (Premarket Approval), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Requlations, Title 21, Parts 800 to 895. A substantially equivalent determination assumes compliance with the Good Manufacturing Practice for Medical Devices: General (GMP) regulation (21 CFR Part 820) and that, through periodic GMP inspections, the Food and Drug Administration (FDA) will verify such assumptions. Failure to comply with the GMP regulation may result in regulatory action. In addition, FDA may publish further announcements concerning your device in the Federal Register.
4
Page 2 - Dr. Belfer
this response to your premarket notification Please note: submission does not affect any obligation you might have under sections 531 through 542 of the Act for devices under the Electronic Product Radiation Control provisions, or other Federal laws or regulations.
This letter will allow you to begin marketing your device as described in your 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.
If you desire specific advice for your device on our labeling requlation (21 CFR Part 801 and additionally 809.10 for in vitro diaqnostic devices), please contact the Office of Compliance at (301) 594-4692. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to
premarket notification" (21 CFR 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its internet address "http://www.fda.gov/cdrh/dsmamain.html".
Sincerely yours,
Timothy A. Ulatowski
Director
Director Division of Dental, Infection Control, and General Hospital Devices Office of Device Evaluation Center for Devices and Radiological Health
Enclosure
5
510(k) Number (if known):_
Snore-Aid® plus
Device Name:
Indications For Use:
Snore-Aid®plus is prescribed_for the patient by the healthcare professional.
A. Snore-Aid®plus is indicated for use in patients with primary snoring or snoring and mild obstructive sleep apnea (OSA) where mandibular advancement and positioning of the tongue can increase pharyngeal air space.
Snore-Aid®plus is indicated to prevent symptoms of nocturnal B. parafunctional jaw activity in patients undergoing treatment for snoring and OSA by mandibular advancement and tongue positioning.
(PLEASE DO NOT WRITE BELOW THIS LINE - CONTINUE ON ANOTHER PAGE IF NEEDED)
Concurrence of CDRH, Office of Device Evaluation (ODE)
| Prescription Use | X |
|---|---|
| Per 21 CFR 801.109) |
OR
Over-The-Counter Use
(Optional Format 1-2-96)
and General Hospital De 510(k) Number
3-1